The Valley Desk

NCT03689972 · Interventional trial

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Overall registry status Completed

Phase 3

Conditions Multiple Sclerosis, Relapsing-Remitting

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov